Mark Wrona, MD
Hospice and Palliative Medicine · Westbrook, MENPI 1003909565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,223, 9.5 times the $129 reported in 2019.
Across 67 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$205
- AstraZeneca$184
- Daiichi Sankyo Inc.$172
- Johnson & Johnson$120
- Sanofi$89
- AbbVie$73
- plus $730 from 22 others
What the payments were for
- Food & beverage$1,47294%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 5 | $205 |
| AstraZeneca | 7 | $184 |
| Daiichi Sankyo Inc. | 10 | $172 |
| Johnson & Johnson(2 entities) | 5 | $120 |
| Sanofi | 3 | $89 |
| AbbVie | 3 | $73 |
| Novartis | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Collegium Pharmaceutical, Inc. | 1 | $58 |
| Stemline Therapeutics Inc. | 3 | $55 |
| Merck | 3 | $48 |
| Sobi, Inc | 2 | $43 |
| Novocure Inc. | 1 | $41 |
| EMD Serono, Inc. | 2 | $35 |
| Caris MPI, Inc. | 2 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $31 |
| Amgen | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Exelixis Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Pfizer | 1 | $16 |
How this compares
Too few hospice and palliative medicine providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 82 | $72,795 |
| Fentanyl | 148 | $16,695 |
| Oxycodone Hcl | 260 | $6,384 |
| Morphine Sulfate ErMorphine Sulfate | 129 | $4,487 |
| Methadone Hcl | 205 | $3,819 |
| Hydromorphone Hcl | 151 | $3,728 |
| Gabapentin | 196 | $3,594 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 80 | $3,030 |
| Lidocaine | 24 | $2,780 |
| Ondansetron OdtOndansetron | 55 | $1,324 |
| Dexamethasone | 87 | $1,195 |
| Duloxetine Hcl | 41 | $1,071 |
| Methylphenidate Hcl | 37 | $1,048 |
| Mirtazapine | 67 | $923 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $780 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Westbrook
- Paul TanBangor$260
- Laura DirectorPortland$142
- Sara HappelPortland$85
- Renee SarettScarborough$82
- Fernando MorenoPortland$65
- Robert DohnerAugusta$64
- Katrina SinkLewiston$59
- Marjorie Zyirek-BaconPortland$50
- Kevin OsgoodBangor$40
- David MartinBangor$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.